| aticaprant (JNJ-67953964) / J&J |
2022-000430-42: a study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. |
|
|
| Ongoing | 3 | 840 | Europe, RoW | Aticaprant, JNJ-67953964, Tablet | Janssen-Cilag International NV, Janssen Research & Development, LLC | Major Depressive Disorder (MDD) Major depressziós zavar (MDD), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000461-41: A study to evaluate the effectiveness of aticaprant as an add on treatment in patients with depression who have not responded sufficiently to their current antidepressant. |
|
|
| Not yet recruiting | 3 | 538 | RoW, Europe | Aticaprant, JNJ-67953964, Tablet | Janssen-Cilag International NV, Janssen Research & Development, LLC | Major Depressive Disorder (MDD), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000439-22: A study to evaluate the effectiveness of aticaprant as an add on treatment in patients with depression who have not responded sufficiently to their current antidepressant. |
|
|
| Ongoing | 3 | 538 | Europe, RoW | Aticaprant, JNJ-67953964, Tablet | Janssen-Cilag International NV, Janssen Research & Development, LLC | Major Depressive Disorder (MDD), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
VENTURA-1, NCT05455684 / 2022-000439-22: A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy |
|
|
| Recruiting | 3 | 538 | Europe, US, RoW | Aticaprant, JNJ-67953964, Placebo | Janssen Research & Development, LLC, Janssen Research & Development, LLC | Depressive Disorder, Major, Anhedonia | 09/24 | 10/24 | | |
VENTURA-2, NCT05550532: A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy |
|
|
| Recruiting | 3 | 710 | Europe, Canada, US, RoW | Aticaprant, JNJ-67953964, Placebo | Janssen Research & Development, LLC | Depressive Disorder, Major, Anhedonia | 10/24 | 10/24 | | |
| Recruiting | 3 | 840 | Europe, US, RoW | Aticaprant, JNJ-67953964 | Janssen Research & Development, LLC, Janssen Research & Development, LLC | Depressive Disorder, Major | 10/25 | 10/25 | | |
2019-000695-41: A clinical study to explore the efficacy of JNJ-67953964 in the treatment of depression |
|
|
| Not yet recruiting | 2 | 180 | Europe | JNJ-67953964-AAA, Capsule | Janssen-Cilag International NV, Janssen Research and Development LLC | Major Depressive Disorder, depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
